ALK and non-small cell lung carcinoma: In the phase I PROFILE 1001 clinical trial, 50 patients with ROS1-rearranged NSCLC were included (as an expansion cohort) alongside ALK-rearranged advance NCLSC patients, all of whom were treated with crizotinib [5,68].